New combo pills for blood pressure and diabetes pass early safety check
NCT ID NCT07598968
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested two experimental oral drugs, HL1113-R1 and HL1113-R2, in 35 healthy adults to see if they are safe and how the body processes them. The drugs are being developed for high blood pressure and type 2 diabetes. Participants took the drugs alone and together in a crossover design. Since this is a Phase 1 study in healthy people, it does not prove the drugs work for these conditions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HL1113-R1 and HL1113-R2 (oral drugs for hypertension and type 2 diabetes)
- What this could lead to
- If successful, this could help develop safer or more effective combination treatments for high blood pressure and type 2 diabetes.
- What could go wrong
- This is an early Phase 1 trial in healthy people, not patients. It only measures safety and drug levels, not whether the drugs actually work for the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
35 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jul 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy adult subjects aged ≥19 years at the time of screening * Subjects with no clinically significant congenital or chronic diseases based on screening, and no clinically significant findings on internal medicine examination (including, if necessary, electroencephalogram \[EEG\], electrocardiogram \[ECG\], chest examination, upper gastrointestinal endoscopy, or gastrointestinal radiography) * etc. Exclusion Criteria: * Subjects who have received medications known to markedly induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 30 days prior to the screening visit * Subjects who have received any medications that may affect the outcome of the study within 10 days prior to the screening visit * etc.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Central Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fat Tissue's chemical signals: a new target for diabetes?
- Inflatable leg cuffs tested as a Two-for-One therapy for high blood pressure and erectile dysfunction
- Can nurses and home monitors tame high blood pressure?
- Can pressing six points on the body help older adults sleep?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Could a quieter, automated blood pressure check help more people control hypertension?